AI English summary of an SEC filing — figures as filed
Becton Dickinson BDXBecton Dickinson said revenues for Q2 of its 2025 fiscal year, the 3 months ended March 31, 2025, were $5,272 million, up 4.5% as reported, 6.0% on a currency-neutral basis and 0.9% on an organic basis compared to $5,045 million in the prior-year period.
Key points
AI summaryBecton Dickinson said revenues for Q2 of its 2025 fiscal year, the 3 months ended March 31, 2025, were $5,272 million, up 4.5% as reported, 6.0% on a currency-neutral basis and 0.9% on an organic basis compared to $5,045 million in the prior-year period.
The company said GAAP diluted earnings per share for Q2 were $1.07, down 42.2% from $1.85 in the prior-year period, while adjusted diluted EPS were $3.35, up 5.7% from $3.17. Net income for the quarter declined to $308 million from $537 million.
Becton Dickinson said BD Medical revenues for Q2 were $2,760 million, up 12.7%, while BD Life Sciences revenues were $1,247 million, down 4.3%, and BD Interventional revenues were $1,264 million, down 2.2%. The company said BD Medical revenues reflected the contribution from the Advanced Patient Monitoring business unit, which was formed upon the closing of the Critical Care acquisition on September 3, 2024.
Becton Dickinson provided adjusted diluted EPS guidance for fiscal 2025 of $14.06 to $14.34, including an estimated tariff impact of approximately $0.25, compared to its prior guidance of $14.30 to $14.60 as of February 5, 2025. The company provided full-year revenue guidance of approximately $21.8 billion to $21.9 billion and organic revenue growth guidance of 3.0% to 3.5%.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Q2 revenues $5,272 million, up 4.5% as reported
Becton Dickinson said revenues for Q2 of its 2025 fiscal year, the 3 months ended March 31, 2025, were $5,272 million, up 4.5% as reported, 6.0% on a currency-neutral basis and 0.9% on an organic basis compared to $5,045 million in the prior-year period.
Source · Based on the filing body and exhibits
Q2 GAAP diluted EPS $1.07, adjusted EPS $3.35
The company said GAAP diluted earnings per share for Q2 were $1.07, down 42.2% from $1.85 in the prior-year period, while adjusted diluted EPS were $3.35, up 5.7% from $3.17. Net income for the quarter declined to $308 million from $537 million.
Source · Based on the filing body and exhibits
Q2 segment revenues: BD Medical up, Life Sciences and Interventional down
Becton Dickinson said BD Medical revenues for Q2 were $2,760 million, up 12.7%, while BD Life Sciences revenues were $1,247 million, down 4.3%, and BD Interventional revenues were $1,264 million, down 2.2%. The company said BD Medical revenues reflected the contribution from the Advanced Patient Monitoring business unit, which was formed upon the closing of the Critical Care acquisition on September 3, 2024.
Source · Based on the filing body and exhibits
Full-year guidance: adjusted EPS $14.06 to $14.34 including estimated tariff impact
Becton Dickinson provided adjusted diluted EPS guidance for fiscal 2025 of $14.06 to $14.34, including an estimated tariff impact of approximately $0.25, compared to its prior guidance of $14.30 to $14.60 as of February 5, 2025. The company provided full-year revenue guidance of approximately $21.8 billion to $21.9 billion and organic revenue growth guidance of 3.0% to 3.5%.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…